Mytos Bio Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mytos Bio Limited - overview
Established
2016
Location
London, -, UK
Primary Industry
Biotechnology
About
Founded in 2016 by its CEO, Ali Afshar, and co-founder, Ignacio Willats, and based in London, UK, Mytos Bio Limited, operates as a biotechnology company that offers a digital platform used for the automated manufacture of any human cell type. In November 2023, Mytos Bio Limited raised USD 19 million in Series A funding led by Buckley Ventures, with participation from IQ Capital and Wing VC. Mytos offers various accelerated drug discovery solutions through the automation of laborious cell culture workflows. The company offers the Mytos Platform, which streamlines various cell culture processes in drug discovery and helps reduce costly contamination in cell cultures.
The platform automates multiple methods for generating neural progenitor cells (NPC), valuable for modelling neurodegenerative diseases. The company plans to use the November 2023 funding to cope with the increasing demand by expediting the production and distribution of Mytos' automated cell production equipment to additional biotechnology and pharmaceutical organizations.
Current Investors
IQ Capital, Wing, Buckley Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.mytos.bio/
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Mytos Bio Limited - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|
| Revenue (USD) | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | - | - | - | - |
| Operating Income (USD) | - | - | - | - |
| Operating Margin | - | - | - | - |
| % EBITDA Margin | - | - | - | - |
| NET Income (USD) | (503,851) | - | - | - |
| % Net Margin | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.